Orzeyful™ (Oveporexton) for Narcolepsy Type 1
The First Medicine to Treat the Underlying Cause of NT1
For decades, narcolepsy type 1 treatment has meant managing symptoms — stimulants for sleepiness, oxybates for cataplexy. Orzeyful works differently: it acts directly at the orexin receptor, supplying the signal that NT1 takes away. It is not a cure, but it is the first medicine aimed at the mechanism rather than the symptoms.
Not Yet Available to Patients — Here's the Honest Timeline
Orzeyful was approved on August 5, 2026, but it cannot be filled yet. The DEA still has to assign its controlled substance schedule, which Takeda expects within 90 days of approval. Only after that will it be distributed — through specialty pharmacy.
We will not promise you a prescription on a date the DEA has not set. What we can tell you is what matters more right now: you cannot be considered for Orzeyful without a documented NT1 diagnosis, and that workup takes months. See how to get diagnostically ready below.
Disclosure: Dr. Jain is a paid speaker and advisor for Takeda (Orzeyful). He holds similar relationships with other pharmaceutical and device manufacturers. These relationships are listed in full on our About page and do not change our clinical recommendations.
Why This Approval Is Different
What Causes Narcolepsy Type 1
NT1 is caused by the loss of neurons that produce orexin (also called hypocretin), the neuropeptide that stabilizes wakefulness. Without it, the boundary between sleep and wake becomes unstable — producing sleep attacks, cataplexy, sleep paralysis, hallucinations, and fragmented nighttime sleep.
What Orzeyful Does About It
Orzeyful is an oral orexin receptor 2 (OX2R) agonist. It acts at the OX2 receptor to supply the signal the missing neurons no longer send. Every prior NT1 medication worked downstream of the problem; this one works at it.
Dosing is twice each morning, not morning and night: 1 mg or 2 mg on awakening, then the same dose again three to five hours later — in the trials, the second dose was taken no later than 1 PM. The maximum is 4 mg per day. A 0.5 mg tablet also exists for patients who need a reduced dose.
Importantly, it is not a cure and not disease-modifying. It does not regenerate the lost orexin neurons or halt the process that destroyed them. NT1 remains lifelong, and the benefit continues only while you take the medication.
Clinical evidence: Approval was supported by two global Phase 3 trials, FirstLight and RadiantLight. Results at week 12, versus placebo:
- • Staying awake (MWT): mean sleep latency improved by 13.8 minutes at 1 mg and 17.2 minutes at 2 mg in FirstLight, and 20.1 minutes at 2 mg in RadiantLight. Patients started at roughly 4–5.5 minutes; the normal range is 20 minutes or more.
- • Daytime sleepiness (Epworth): scores fell by 8.0 points at 1 mg and 9.8 at 2 mg in FirstLight, and 9.5 at 2 mg in RadiantLight, from baselines around 17–19. A score of 10 or below is considered normal.
- • Cataplexy: weekly attack rates fell to roughly a third to a quarter of placebo. In RadiantLight, the 2 mg group went from about 33 episodes per week to about 7.
Source: ORZEYFUL (oveporexton) US Prescribing Information, Takeda, Rev. 8/2026, Section 14, Table 3. These are trial averages, not predicted outcomes for any individual — your response may differ.
Who Orzeyful Is — and Isn't — For
This approval is narrower than the headlines suggest. Please read this part carefully before getting your hopes up.
Approved For:
- ✓ Narcolepsy type 1 — narcolepsy with cataplexy
- ✓ Adults (18 and over)
- ✓ Patients with a documented, objectively confirmed NT1 diagnosis
Not Approved For:
- ✗ Narcolepsy type 2 (without cataplexy)
- ✗ Idiopathic hypersomnia
- ✗ Children and adolescents
- ✗ Excessive daytime sleepiness from sleep apnea or shift work
If you have NT2, oxybates, Wakix, Sunosi and modafinil remain approved options. For idiopathic hypersomnia, Xywav is the only FDA-approved medication — the others are used off-label, which is common and often appropriate but worth understanding. That conversation is worth having.
How to Be Ready the Day It Launches
The bottleneck is not the medication. It is the diagnosis. Confirming narcolepsy type 1 requires an overnight in-lab study followed by next-day testing — a two-day booking that our lab schedules further out than a routine consultation. Ask our office for the current MSLT wait when you call.
Step 1: The Overnight PSG
An in-lab polysomnogram rules out sleep apnea as the cause of your sleepiness and confirms you slept enough for the next-day test to be valid. A home sleep test cannot do this.
Step 2: The MSLT
The Multiple Sleep Latency Test — five scheduled naps the following day, measuring how fast you fall asleep and whether you enter REM. This is the definitive objective test, and it is what payers and prior authorization reviewers will look for.
Step 3: Documenting Cataplexy (and the Type 1 Distinction)
Orzeyful is approved for type 1 specifically, so the clinical record has to establish cataplexy — or, in selected cases, low CSF hypocretin. Getting this documented properly now is what separates a smooth authorization later from a denial.
Why booking now is genuinely the right move: in-lab PSG plus next-day MSLT is a two-day booking, and demand for these slots will rise once Orzeyful reaches pharmacies. Starting the evaluation now means you are diagnostically ready whenever launch happens, rather than joining a queue that forms that week. This is worth doing regardless of Orzeyful: an objectively confirmed diagnosis changes your options across every narcolepsy therapy, and supports disability and accommodation claims.
Side Effects and Safety — The Part Most Sites Skip
Orzeyful has a side effect profile you should understand before you decide you want it.
Most Common Adverse Effects (Phase 3 trials)
- Insomnia: 60% at the 2 mg dose and 55% at 1 mg, versus 1% on placebo. This is the one to take seriously — a drug that restores wake signaling can make it genuinely hard to fall asleep at night.
- Urinary frequency: 58% at 2 mg and 53% at 1 mg, versus 5% on placebo.
- Urinary urgency: 16% at 2 mg and 15% at 1 mg, versus 1% on placebo.
- Excessive salivation: 8% (1 mg) and 7% (2 mg), versus 0% on placebo.
- Elevated creatine phosphokinase (CPK): asymptomatic elevations above five times the upper limit of normal in 11% on Orzeyful versus 5% on placebo. Two patients had markedly elevated CPK together with elevated liver enzymes and both stopped the medication. Report unexplained muscle pain, weakness, or dark urine to your prescriber.
- Elevated LDL cholesterol: LDL above 160 mg/dL in 32% versus 20% on placebo, with a mean rise of 17.6 mg/dL versus 4.4. This is a larger signal than the CPK finding and is worth tracking.
- Day-one blood pressure and heart rate increases: systolic BP rose more than 20 mmHg in 22% versus 13% on placebo, and heart rate more than 15 bpm in 30% versus 22%. These attenuated by week 12.
About the Insomnia — Useful Detail
The label gives a clearer picture than the headline percentage. Roughly 90% of insomnia events began within the first two days, about 63% resolved within a week, severe insomnia occurred in 1.5% of patients, and no one discontinued because of it. The label's own guidance is to consider a dose reduction if insomnia persists beyond seven days with a functional impact. Taking both doses in the morning, as directed, matters here.
Abuse Potential
The label includes an abuse-potential section. In a human abuse-potential study, drug liking was greater than placebo and similar to or lower than phentermine, a Schedule IV substance. This is part of why the DEA is reviewing its scheduling — the delay is a substantive regulatory step, not only paperwork.
Contraindications and Cautions
- • Contraindicated in patients taking strong CYP3A inhibitors — this rules out a number of common medications, so bring your full list to your visit
- • Moderate CYP3A inhibitors require a dose reduction to 0.5 mg twice each morning (1 mg per day total)
- • Strong and moderate CYP3A inducers should be avoided — phenytoin reduced drug exposure by 81%
- • Avoid in severe hepatic impairment (Child-Pugh C)
- • Avoid in severe renal impairment (eGFR under 15 mL/min, including patients on dialysis)
- • Only one patient aged 65 or older was enrolled across both Phase 3 trials, so experience in older adults is very limited
This page is general education, not prescribing advice or a substitute for the full prescribing information. Whether Orzeyful is appropriate for you is a decision to make with a physician who has reviewed your history, medications, and objective test results. For complete safety information, see the official ORZEYFUL prescribing information from Takeda. There is also a pregnancy exposure registry for narcolepsy medications at 1-877-371-0309.
Common Questions about Orzeyful (Oveporexton) for Narcolepsy Type 1
Start the Workup Now, Not After Launch
Orzeyful candidacy requires a confirmed narcolepsy type 1 diagnosis, and that takes an in-lab study plus next-day testing. Starting now means you are diagnostically ready whenever the medication does reach patients.
Serving Frisco, Plano, Dallas, Allen, and McKinney • Board-Certified Sleep Medicine
Not sure whether you have narcolepsy type 1? Read our full narcolepsy and hypersomnia overview for how diagnosis and the other treatment options work.